Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus dose-escalation study in lymphangioleiomyomatosis
2010-019825-32Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in lymphangioleiomyomatosis (LAM), sponsored by Novartis. Primary endpoints: Safety of everolimus, Pharmacokinetics of everolimus and 1 more. Started May 2010; status: completed.
02
Drugs
everolimus
03
Conditions
lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on 2010-019825-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019825-32.